This comparative study uses data from the US Food and Drug Administration Adverse Event Reporting System database to investigate the association between treatment with nivolumab in combination with epidermal growth factor receptor-tyrosine kinase inhibitors and interstitial pneumonitis in patients with non–small cell lung cancer.
from Cancer via ola Kala on Inoreader http://ift.tt/2D2ZT37
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου